Zevra Therapeutics (NASDAQ:ZVRA) Trading 5.2% Higher – Time to Buy?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA)’s share price rose 5.2% during trading on Friday . The stock traded as high as $9.36 and last traded at $9.5490. Approximately 230,059 shares changed hands during trading, a decline of 77% from the average daily volume of 992,670 shares. The stock had previously closed at $9.08.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Weiss Ratings restated a “sell (d+)” rating on shares of Zevra Therapeutics in a research report on Friday, January 9th. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Cantor Fitzgerald lowered their price target on Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. HC Wainwright set a $26.00 price target on shares of Zevra Therapeutics in a research report on Tuesday, December 30th. Finally, Canaccord Genuity Group decreased their price objective on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, November 6th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Zevra Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.80.

Zevra Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.46, a current ratio of 8.62 and a quick ratio of 8.57. The company has a market cap of $504.99 million, a price-to-earnings ratio of 19.09 and a beta of 1.08. The stock has a 50-day moving average price of $8.68 and a 200 day moving average price of $9.59.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%.The business had revenue of $26.06 million during the quarter, compared to analysts’ expectations of $26.64 million. As a group, analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. CWM LLC increased its holdings in Zevra Therapeutics by 399.5% during the 3rd quarter. CWM LLC now owns 2,872 shares of the company’s stock worth $27,000 after purchasing an additional 2,297 shares in the last quarter. Ameritas Investment Partners Inc. grew its holdings in shares of Zevra Therapeutics by 30.0% during the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after buying an additional 1,280 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after buying an additional 4,475 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Zevra Therapeutics by 617.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after buying an additional 8,552 shares during the last quarter. Finally, Creative Planning bought a new stake in Zevra Therapeutics in the 2nd quarter valued at approximately $92,000. 35.03% of the stock is owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.